No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
Toho Holdings Co., Ltd. serves as a leading wholesaler of pharmaceutical and healthcare products throughout Japan. Its extensive product range includes prescription and over-the-counter medications, reagents, medical devices and supplies, and health foods, in addition to offerings for preventive, clinical, community, and home-based medical and nursing care. Beyond distribution, the company provides comprehensive support services like developing and selling customer-focused software, assisting with the establishment of new medical facilities and pharmacies, delivering management consulting, offering medical assistance, and facilitating personnel recruitment. Toho Holdings also operates dispensing pharmacies, manufactures and distributes generic drugs, acts as a site management organization (SMO) to support clinical trials for various healthcare institutions, and supplies specialized software to the medical sector. Among its technological solutions are customer support systems such as ENIF for pharmaceutical ordering, ENI-Pharmacy for streamlining dispensing and prescribing processes, LXMATE HeLios for medical appointments, KAITOS for online medical consultations and medication guidance, ENIFwin for inventory control in large hospitals, the ENIFvoice series for voice-activated electronic medication history recording, and ENIF Nurse for home-visit nurse operational support, along with diverse logistics systems. The company, founded in 1948, is headquartered in Tokyo, Japan.
www.tohohd.co.jpNo one on the platform currently holds 8129.T.
No tracked institution reports a position in 8129.T as of their last filing.
No one on the platform has traded 8129.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | 6.0% | 5.6% | — | — | — |
| Rev. Growth % | 2.3% | 5.1% | ||||
| Profit Margin % | 1.1% | 1.2% | 1.1% | |||
| Free Cash Flow Margin % | 0.8% | 0.7% | 0.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.62T | +4.9% | $177.95 | $175.13–$181.39 | — | 1 |
| 2028 | $1.66T | +2.5% | $199.39 | $188.53–$210.42 | — | 3 |
| 2029 | $1.72T | +3.3% | $222.21 | $215.02–$229.40 | — | 2 |
| 2030 | $1.77T | +2.9% | $241.22 | $237.40–$245.87 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $45.48 | $36.24 | -20.3% |
| 2026-05-13 | $45.11 | $44.13 | -2.2% |
| 2026-02-12 | $114.42 | $127.93 | +11.8% |
| 2025-11-12 | $32.45 | $45.51 | +40.2% |
| 2025-08-05 | $28.82 | $53.61 | +86.0% |
| 2025-05-14 | $97.67 | $151.57 | +55.2% |
| 2025-02-07 | $77.36 | $75.92 | -1.9% |
| 2024-11-08 | $69.69 |
| $56.96 |
| -18.3% |
| +0.91% |
| $231.1B |
| — |
| 4521.TKaken Pharmaceutical Co., Ltd. | $3905.00 | +0.51% | $147.9B | — |
| 4530.THisamitsu Pharmaceutical Co., Inc. | $6040.00 | +0.00% | $425.2B | — |
Source: Financial Modeling Prep · peers by sector/industry